Skip to main content
Industry News
CAR T-cell therapy response rate higher among older adults

A midstage trial assessing the chimeric antigen receptor T-cell therapy idecabtagene vicleucel, developed by bluebird bio and Bristol Myers Squibb, found adults older than 65 with relapsed or refractory multiple myeloma had higher response rates than the overall study group. The findings were presented at the Transplantation & Cellular Therapy Meetings.

Full Story: